<div>
  <ul>
    <li>
      <p>
        Ophelia, a New York-based telepsychiatry platform, has raised USD 50 million in a Series B funding round led by Tiger Global Management, with participation from Menlo Ventures, General Catalyst, Refactor Capital, 640 Oxford Ventures, Interplay Ventures, and several individual investors. This brings the company&rsquo;s total funding to USD 68 million.
      </p>
    </li>
  </ul>
  <ul>
    <li>
      <p>
        The funds will be used to expand its opioid use disorder (OUD) treatment solutions to grow the market reach nationwide as well as to develop its platform further. The proceeds will also be used to integrate with more payors and partners. The company aims to cover 80% of the OUD patients who are not engaged with the health system.
      </p>
    </li>
  </ul>
  <ul>
    <li>
      <p>
        The latest funding comes after Ophelia concludes its Series A funding round of USD 15 million in April 2021.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.globenewswire.com/news-release/2021/12/14/2351846/0/en/Ophelia-Raises-50-Million-Series-B-Led-by-Tiger-Global-to-Expand-Its-Novel-Approach-to-Opioid-Addiction-Treatment.html">
      Globe Newswire
    </a>
  </p>
  <p>
    <a href="https://www.mobihealthnews.com/news/opioid-use-recovery-tool-ophelia-scores-50m">
      Mobi Health News
    </a>
  </p>
</div>


All Updates

Ophelia raises USD 50 million in Series B funding